Trevena Inc. (Nasdaq: TRVN) announced positive Phase 2b study results of its
moderate to severe acute postoperative pain treatment TRV130 sending the stock price soaring $3.21 to $9.21.
Positive study results for Trevena
September 01, 2015 at 15:19 PM EDT
